Home/Pipeline/REQORSA

REQORSA

NSCLC

Phase 1/2Status Unclear (ONC-001)

Key Facts

Indication
NSCLC
Phase
Phase 1/2
Status
Status Unclear (ONC-001)
Company

About Genprex

Genprex is a clinical-stage biotech focused on developing gene therapies for cancer and diabetes using its proprietary Oncoprex® non-viral delivery platform. The company's strategy centers on advancing its lead candidate, REQORSA, through mid-stage trials in non-small cell and small cell lung cancer, with programs supported by multiple FDA Fast Track and Orphan Drug designations. While still pre-revenue, Genprex aims to address large, underserved patient populations by combining its platform technology with established therapies to overcome treatment resistance.

View full company profile

About Genprex

Genprex is a clinical-stage biotech focused on developing gene therapies for cancer and diabetes using its proprietary Oncoprex® non-viral delivery platform. The company's strategy centers on advancing its lead candidate, REQORSA, through mid-stage trials in non-small cell and small cell lung cancer, with programs supported by multiple FDA Fast Track and Orphan Drug designations. While still pre-revenue, Genprex aims to address large, underserved patient populations by combining its platform technology with established therapies to overcome treatment resistance.

View full company profile

Therapeutic Areas

Other NSCLC Drugs

DrugCompanyPhase
HBM7008Harbour BioMedPhase 1
HBM7004Harbour BioMedDiscovery
LR19125AVEO OncologyPre-clinical